glp 1 diabetes GLP-1-based therapies for type 2 diabetes: from single, dual and triple agonists to endogenous GLP-1 production and L-cell differentiation | Diabetology & Metabolic Syndrome GLP-1R and Diabetes
Description
& Beinborn, M
Pyke C, Heller RS, Kirk RK, Orskov C, Reedtz-Runge S, Kaastrup P, et al
[DOI] [PubMed] [Google Scholar] 80.Gastaldelli A, Cusi K, Fernandez Lando L, Bray R, Brouwers B, Rodriguez A
Verify availability in your state before enrolling
Ongoing research into nutritional and exercise interventions, as well as novel pharmacological agents such as myostatin/activin pathway inhibitors (243) or agents targeting the apelin pathway (244) holds promise for preserving lean mass and improving overall health in patients undergoing treatment with GLP-1 and dual GIP/GLP-1 receptor agonists
Learn more:
